Skip to main content

3 Result(s)

within Jonathan W Goldman Remove this filter Biomedicine, general Remove this filter

and

  1. No Access

    Article

    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

    Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific neoantigens hold promise for providing long-term clinical benefit to patients with cancer. Here we evaluated safety and tole...

    Amy R. Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart… in Nature Medicine (2024)

  2. Article

    Open Access

    Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

    This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, cau...

    Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato… in Targeted Oncology (2024)

    Download PDF (577 KB) View Article

  3. Article

    Open Access

    A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

    This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.

    Jonathan W Goldman, Robert N Raju, Gregory A Gordon, Iman El-Hariry… in BMC Cancer (2013)

    Download PDF (721 KB) View Article